Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab | Zendy

F. Poizeau | Zendy; Emmanuel Nowak | Zendy; Sandrine Kerbrat | Zendy; Béranger Le Nautout | Zendy; C. Droitcourt | Zendy; MilouDaniel Drici | Zendy; É. Sbidian | Zendy; B. Guillot | Zendy; H. Bachelez | Zendy; Hafid Aït-Oufella | Zendy; André Happe | Zendy; Emmanuel Oger | Zendy; A. Dupuy | Zendy

Open Access

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab

Author(s) -

F. Poizeau,

Emmanuel Nowak,

Sandrine Kerbrat,

Béranger Le Nautout,

C. Droitcourt,

MilouDaniel Drici,

É. Sbidian,

B. Guillot,

H. Bachelez,

Hafid Aït-Oufella,

André Happe,

Emmanuel Oger,

A. Dupuy

Publication year - 2020

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2020.2977

Subject(s) - ustekinumab , medicine , odds ratio , psoriatic arthritis , randomized controlled trial , disease , adalimumab

Ustekinumab, a monoclonal antibody targeting interleukin 12/23p40 (IL-12/23p40), is effective in the treatment of moderate to severe psoriasis, psoriatic arthritis, and Crohn disease. In 2011, a meta-analysis of randomized clinical trials reported a potential risk of severe cardiovascular events (SCEs) within the first few months after the initiation of anti-IL-12/23p40 antibodies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research